Dan O'Day, Gilead CEO (Andrew Harnik/AP Images)

Gilead wins ap­proval for long-act­ing HIV in­jec­tion af­ter re­solv­ing vial con­cerns

Gilead fi­nal­ly gained FDA ap­proval on Thurs­day for lenaca­pavir, its close­ly-watched cap­sid in­hibitor for HIV-1, the most com­mon type of HIV.

Lenaca­pavir will be mar­ket­ed in the US as Sun­len­ca for heav­i­ly pre­treat­ed HIV-1 pa­tients who are fail­ing their cur­rent an­ti­retro­vi­ral reg­i­men. The long-act­ing sub­cu­ta­neous in­jec­tion is ad­min­is­tered just twice a year, of­fer­ing an al­ter­na­tive to cum­ber­some dai­ly pill reg­i­mens.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters